News
NKTX
3.380
+2.42%
0.080
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
Simply Wall St · 12h ago
Weekly Report: what happened at NKTX last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at NKTX last week (0622-0626)?
Weekly Report · 06/29 10:17
Nkarta joins H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 06/26 12:45
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Barchart · 06/26 07:45
Nkarta initiated with a Buy at TD Cowen
TipRanks · 06/23 11:33
Phil Nadeau Reiterates Buy on Nkarta, Citing Differentiated NK Cell Platform and CD19 CAR NK Therapy as Key Long-Term Value Drivers
TipRanks · 06/23 09:55
NKARTA INC <NKTX.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/23 09:45
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Reuters · 06/23 07:27
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Nkarta (NKTX)
TipRanks · 06/22 15:00
Weekly Report: what happened at NKTX last week (0615-0619)?
Weekly Report · 06/22 10:26
Weekly Report: what happened at NKTX last week (0608-0612)?
Weekly Report · 06/15 10:27
These healthcare stocks are combining strong gains with reasonable prices
Seeking Alpha · 06/12 10:38
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
TipRanks · 06/11 22:25
Weekly Report: what happened at NKTX last week (0601-0605)?
Weekly Report · 06/08 10:22
Weekly Report: what happened at NKTX last week (0525-0529)?
Weekly Report · 06/01 10:27
The $13 Million Company Teaching the Immune System to Hunt Cancer
Barchart · 05/29 08:00
Weekly Report: what happened at NKTX last week (0518-0522)?
Weekly Report · 05/25 10:31
Weekly Report: what happened at NKTX last week (0511-0515)?
Weekly Report · 05/18 10:30
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Simply Wall St · 05/15 11:13
More
Webull provides a variety of real-time NKTX stock news. You can receive the latest news about Nkarta, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.